For over a decade, Nova Eye Medical’s proprietary iTrack™ canaloplasty microcatheter has been used across the globe, combining catheterization and pressurized viscodilation over the entire 360 degrees of the conventional outflow pathway to effectively treat over 100,000 glaucoma patients.
Building on that success – and the clinically proven effectiveness of iTrack technology – Nova Eye have introduced the ground- breaking iTrack Advance. The iTrack Advance takes the established effectiveness, accuracy and reliability of the original iTrack and combines it with an ergonomic, easy-to-use handheld injector and custom-designed cannula, all making for a more straightforward procedure. Notably, iTrack Advance is cleared for use as a standalone procedure and in combination with cataract surgery.
Developed through extensive research and detailed feedback from surgeons, the all-in-one handheld injector allows for streamlined insertion of the microcatheter into Schlemm’s canal. It also enables predictable, controlled and smooth advancement and retraction of the microcatheter through the canal. Measuring just 200 microns in diameter, the microcatheter comprises a sophisticated set of inner workings, including Nova Eye’s signature fiber optic for illuminating the distal tip.
Avoiding the use of a stent and preserving vital tissue, canaloplasty can help surgeons effectively reduce IOP in cases of mild to moderate glaucoma, while preserving the viability of future treatment options. As a 360° procedure that addresses the entire conventional outflow pathway, including the trabecular meshwork, Schlemm’s canal and the collector channels, iTrack Advance literally treats glaucoma from all angles.
By maintaining the natural pathway of aqueous outflow, iTrack Advance lets you work with patient physiology rather than against it – this is in stark contrast to most other glaucoma procedures, which are designed to bypass or remove the points of outflow resistance.
iTrack Advance is specifically designed to make canaloplasty more accessible to more surgeons. The former iTrack canaloplasty was more technically challenging to use. And with complexity comes hesitance, meaning that the adoption rate of canaloplasty has been lower than its excellent effectiveness and safety profile would suggest. Thanks to Nova Eye’s close links with surgeons, specialist academics, and wider industry – as well as rigorous testing, more ophthalmologists can be confident in their ability to use iTrack Advance and add canaloplasty to their glaucoma armamentarium.
Disclaimer:
iTrack™ Advance has been cleared for the indication of fluid infusion or aspiration during surgery, and for catheterization and viscodilation of Schlemm’s canal for the reduction of intraocular pressure (IOP) in adult patients with open-angle glaucoma. iTrack™ Advance has a CE Mark (Conformité Européenne) for the treatment of open-angle glaucoma. iTrack™ Advance is not available for use or sale in the USA.
